Home > Insider Trading > Filing (0000919574-19-007402)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
834365	Biolife Solutions Inc	BLFS	Electromedical & Electrotherapeutic Apparatus (3845)	943076866

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1534260	Casdin Partners Gp, Llc	1350 Avenue Of The Americas Suite 2600 New York NY 10019	No	No	Yes	No
1534261	Casdin Capital, Llc	1350 Avenue Of The Americas Suite 2600 New York NY 10019	No	No	Yes	No
1534264	Eli Casdin	1350 Avenue Of The Americas Suite 2600 New York NY 10019	No	No	Yes	No
1534265	Casdin Partners Master Fund, L.p.	1350 Avenue Of The Americas Suite 2600 New York NY 10019	No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock, Par Value $.001 Per Share	Acquisiton	2019-11-19	20,000	$15.15	2,448,571	No	4	P	Direct
Common Stock, Par Value $.001 Per Share	Acquisiton	2019-11-20	20,000	$15.68	2,468,571	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Direct
No	4	P	Direct

Footnotes

The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $14.93 to $15.26 per share, inclusive. The Reporting Persons undertake to provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, upon request, full information regarding the number of shares purchased at each separate price.
The securities are owned directly by Casdin Partners Master Fund, LP and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to Casdin Partners Master Fund, LP, (ii) Casdin Partners GP, LLC, the general partner of Casdin Partners Master Fund LP, and (ii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC.
The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $15.37 to $16.08 per share, inclusive. The Reporting Persons undertake to provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, upon request, full information regarding the number of shares purchased at each separate price.